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a b s t r a c t
While the 2002–2003 outbreak of severe acute respiratory syndrome (SARS) resulted in 774 deaths,
patients who were affected with mild pulmonary symptoms successfully recovered. The objective of the
present work was to identify, using SARS coronavirus (SARS-CoV) mouse infection models, immune factors
responsible for clearing of the virus. The elimination of pulmonary SARS-CoV infection required the
activation of B cells by CD4þ T cells. Furthermore, passive immunization (post-infection) with homologous
(murine) anti-SARS-CoV antiserum showed greater elimination efﬁcacy against SARS-CoV than that with
heterologous (rabbit) antiserum, despite the use of equivalent titers of neutralizing antibodies. This
distinction was mediated by mouse phagocytic cells (monocyte-derived inﬁltrating macrophages and
partially alveolar macrophages, but not neutrophils), as demonstrated both by adoptive transfer from
donors and by immunological depletion of selected cell types. These results indicate that the cooperation
of anti-SARS-CoV antibodies and phagocytic cells plays an important role in the elimination of SARS-CoV.
& 2014 Elsevier Inc. All rights reserved.
Introduction
From November 2002 to July 2003, the world suffered a global
outbreak of severe acute respiratory syndrome (SARS). The disease,
which resulted in 8098 cases with 774 deaths, was caused by a novel
type of coronavirus, termed SARS-CoV, (http://www.who.int/csr/sars/
country/table2004_04_21/en/index.html). Patients with SARS usually
developed a high fever followed by clinical symptoms of lower
respiratory tract disease. In severe cases, the patients presented with
acute respiratory distress syndrome, characterized by diffuse alveolar
damage, and ultimately died (Peiris et al., 2003a, 2003b; Fowler et al.,
2003; Wang and Chang 2004). The hallmarks of severe cases of SARS
included high viral titer, systemic infection, lymphopenia, and over-
production of proinﬂammatory cytokines/chemokines (often referred
to as a “cytokine storm”) (Wong et al., 2004; Huang et al., 2005;
Cameron et al., 2007). However, there has been no subsequent
consensus regarding which treatment, if any, beneﬁted SARS patients
during the outbreak (Stockman et al., 2007).
The development of an effective treatment strategy for SARS
cases will require clarifying the precise mechanisms by which host
immune responses control SARS-CoV infection. Cumulative evi-
dence suggests that patients who recovered from SARS possessed
speciﬁc acquired immunity based on both T and B cells (Yang et al.,
2006, 2007; Li et al., 2008; Fan et al., 2009). However, the effector
cells or molecules that act to eliminate SARS-CoV during the acute
phase of the infection remain unclear. As the extensive outbreak of
SARS has not recurred since 2003, the mechanisms by which
SARS-CoV infection causes the pathogenesis and host immune
responses has been investigated using adequate animal infectious
models (Roberts et al., 2005, 2007; Nagata et al., 2008; Zhao et al.,
2009; Zhao and Perlman, 2010). Lethal disease in BALB/c mice
infected with a mouse-adapted strain of SARS-CoV, MA15, showed
a lack of activation of innate immune response, resulting in a
barely detectable antivirus T cell response (Zhao et al., 2009).
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On the other hand, aged BALB/c mice that were infected with a
human clinical isolate of SARS-CoV (Urbani strain) successfully
eliminated the invasive virus within 1 week post-infection;
these mice exhibited high and prolonged levels of viral replica-
tion, signs consistent with clinical symptoms, and pathologic
changes in the lung resembling those seen in elderly SARS
patients (Roberts et al., 2005). Therefore, the infection of these
aged mice is considered a model for the successful elimination
of SARS-CoV by host immune responses. A recent study reported
that CD4þ T cells play an important role in the control of SARS-
CoV infection (Chen et al., 2010). These researchers also
reported an important role for innate defense mechanisms in
controlling SARS-CoV infection, as demonstrated by the clear-
ance of SARS-CoV over 9 days post-infection (dpi) in BALB/c
mice depleted of both CD4þ and CD8þ T cells (Chen et al., 2010).
These results suggest that both innate and adaptive immune
responses are essential for controlling SARS-CoV infection.
Nonetheless, the identity and role of effector cells and mole-
cules participating in the elimination of SARS-CoV during the
acute phase of SARS remain largely unknown.
In this study, we attempted to identify the types of immune
cells that contribute to clearing SARS-CoV during the acute phase
of the infection. This work employed several murine models in
which hosts were deﬁcient for (e.g., depleted via speciﬁc anti-
bodies or lacking via immunodeﬁciency) or supplemented with
(e.g., by adoptive transfer) individual immunologic effectors. We
demonstrate that phagocytic cells (including monocyte-derived
inﬁltrating macrophages and partially alveolar macrophages)
play an important role in the elimination of SARS-CoV in mouse
models of infection.
Results
Adaptive immune responses are essential for the elimination of
pulmonary-infected SARS-CoV
As a ﬁrst step, we conﬁrmed the time course of viral titers in the
lungs of aged (46 months old) BALB/c mice, young (7 weeks old)
BALB/c mice, and young (8 weeks old) SCID mice following infection
with SARS-CoV Vietnam/NB-04/2003. The intranasal (i.n.) infection
of aged BALB/c mice with SARS-CoV resulted in over 108 median
tissue culture infectious dose (TCID50)/g lung tissue at 2 dpi
(Fig. 1A). The infected mice exhibited histological signs of severe
pneumonia, including interstitial cell thickening, immune cell
inﬁltration, and epithelial damage in the bronchus, at 9 dpi and
21 dpi (Fig. 1B(c and d)). These results were similar to those of the
previous reports that used another SARS-CoV strain such as the
Urbani strain (Roberts et al., 2005). In the present work, SARS-CoV
was detected in aged mice starting as early as 2 dpi (Fig. 1A). The
observed titers in the aged-mouse model were considerably higher
than those seen in infected young BALB/c mice, which did not show
apparent histological signs of pneumonia (Fig. 2B). Titers in the
aged mice remained high (107 TCID50/g lung tissue) at 6 dpi
(Fig. 1A). However, the titers decreased to levels below the lower
limit of detection (LLOD; o1000 TCID50/g lung tissue) in the lungs
of aged BALB/c mice and young BALB/c mice at 9 dpi (Fig. 1A). In
contrast, young SCID mice, which lack functional T and B cells, were
persistently infected with SARS-CoV during the experimental per-
iod (through 21 dpi, as shown in Fig. 1A). At this time, SCID mice did
not exhibit histological signs of severe pneumonia at 9 and 21 dpi,
although a high viral titer was detected in the lungs of these
animals during the experimental period (Fig. 1B(g and h) and C).
Recently, Zhao and Perlman (2010) obtained similar results suggest-
ing that a mouse-adapted mutant of SARS-CoV (viral strain MA15)
persistently infected RAG1 knockout mice (C57BL/6 background),
animals that also lack T and B cell populations. Taken together, these
results suggested that the pathogenesis of SARS does not correlate
with the direct cytopathic effect of SARS-CoV. To investigate the
effect of adaptive immune responses on clearance of pulmonary-
infected SARS-CoV, either naïve splenocytes (obtained from BALB/c
mice) or sensitized splenocytes (obtained from SARS-CoV-infected
(9 dpi) BALB/c mice) were adoptively transplanted into naïve SCID
mice 1 day before SARS-CoV infection. As shown in Fig. 1D, the SCID
mice that received naïve splenocytes eliminated SARS-CoV from
their lungs as early as the BALB/c mice did. The SCID mice
transplanted with SARS-CoV-sensitized splenocytes of BALB/c mice
eliminated SARS-CoV more rapidly than mice transplanted with
naïve splenocytes, although the initial pulmonary viral titers were
effectively the same in all groups of SCID mice at 2 dpi, with or
without the transfer of splenocytes. Only one of the SCID mice that
received sensitized splenocytes showed detectable lung pulmonary
viral titer (3.5104 TCID50/g lung) at 6 dpi; titers in the remaining
3 animals of this group (n¼4/time point) were below the LLOD. The
SCID mice transplanted with naïve- or sensitized-splenocytes
derived from aged BALB/c mice did not show histological signs of
severe pneumonia at 9 dpi, although inﬁltration of immunocompe-
tent cells around bronchioles (arrows) was partially observed in the
lung of both groups (Fig. 1E). These results indicated that induction
of adaptive immune responses is essential for the clearance of
pulmonary-infected SARS-CoV.
CD4þ T cells play an important role in the elimination of SARS-CoV-
infected pulmonary cells, but this antiviral effect is indirect
To identify the host defense(s) involved in the elimination of
SARS-CoV in the lung, we depleted CD4þ cells and/or CD8þ cells
in BALB/c mice before and after SARS-CoV infection. Depletion of
the CD4þ cells or CD8þ cells was performed by intravenous (i.v.)
injection of (respectively) monoclonal antibody (mAb) GK1.5 or
53.6; control experiments demonstrated that injection of these
mAbs produced virtually complete depletion of the correspond-
ing cell populations (Fig. 1F). The CD4þ T cell-depleted BALB/c
mice and the CD4þ T and CD8þ T cell-double-depleted BALB/c
mice failed to eliminate the SARS-CoV-infected pulmonary cells
by 9 dpi (Fig. 1G). In contrast, the CD8þ T cell-depleted BALB/c
mice largely eliminated the SARS-CoV-infected pulmonary cells
by 9 dpi (Fig. 1G). Recently, Chen et al. (2010) reported that both
CD4þ T cells and neutralizing antibodies (following antibody
response) play an important role in the elimination of SARS-CoV-
infected pulmonary cells. However, it remains unclear whether
the elimination of the virus in the present work and by Chen et al.
(2010) reﬂects direct antiviral effect(s) by CD4þ T cells and/or B
cells. Notably, several reports have demonstrated the presence of
CD4þ T cells with cytotoxic activity during persistent viral
infection, including infection by human immunodeﬁciency virus,
human cytomegalovirus, and Epstein–Barr virus (Appay et al.,
2002; Casazza et al., 2006; Landais et al., 2004). Furthermore,
CD4þ T cell-mediated control of a γ-herpes virus in B cell-
deﬁcient mice is mediated by interferon-gamma (IFN-γ)
(Christensen et al., 1999). In the present work, we found that
SARS-CoV persistently infected the lung of nude (T cell-deﬁcient)
mice, as well as SCID mice (deﬁcient of T cell and B cell), without
inducing histological signs of pneumonia (Fig. 2A and B). There-
fore, we investigated (using either of two models) whether CD4þ
T cells could directly eliminate SARS-CoV via IFN-γ secretion. Our
ﬁrst model consisted of the adoptive transfer, 1 day before SARS-
CoV infection, of CD4þ cells (1107 cells/mouse) from BALB/c
mice into nude mice and SCID mice. The SCID mice that received
the CD4þ T cell transfer did not eradicate SARS-CoV infection by
9 dpi (Fig. 2C). In contrast, nude mice that received the same
quantity of CD4þ cells decreased the pulmonary viral titer below
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the LLOD between 6 and 9 dpi (Fig. 2D). For our second model, we
investigated the effect of IFN-γ on the elimination of SARS-CoV
by using IFN-γ-deﬁcient mouse models. The IFN-γ-deﬁcient mice
and the SCID mice that received splenocytes from IFN-γ deﬁcient
mice controlled the SARS-CoV infection as well as the wild-type
mice did (Fig. 2E). These results demonstrated that CD4þ T cells
are an essential cell type for the control of SARS-CoV infection,
and that the effect of this cell fraction is indirect.
B cells and anti-SARS-CoV antibodies contribute to the control of
SARS-CoV infection
The above results showed that SARS-CoV infection could be
controlled both by nude mice which received CD4þ cells and by
CD8þ cell-depleted BALB/c mice, suggesting that B cell is implicated in
the elimination of SARS-CoV. So far, there are multiple studies that
demonstrated the prophylactic effect of neutralizing antibodies against
Fig. 1. CD4þ T cells play an important role in the control of SARS-CoV infection. (A–C) aged BALB/c mice (n¼4–7/time point), young BALB/c mice (n¼5–10/time point),
and young SCID mice (n¼4–8/time point) were infected intranasally with 1105 TCID50 of SARS-CoV Vietnam strain. (A) Virus titers in the lung (TCID50/g lung tissue)
of aged BALB/c mice (closed circles), young BALB/c mice (gray circles), or young SCID mice (open squares) sacriﬁced at 2, 4, 6, 9, or 21 dpi (except for 20 dpi in young
BALB/c mice). npo0.05, nnpo0.01 (compared with young BALB/c mice and SCID mice at the respective time point). N.D.: not detected. (B) Representative lung sections
(hematoxylin and eosin staining; section thickness 4 μm) from aged BALB/c mice at 9 dpi (a and c) and 21 dpi (b and d) and from young SCID mice at 9 dpi (e and g) and
21 dpi (f and h). For all micrographs, original magniﬁcation is 200 . (C) Detection of virus-infected cells in the lungs at 2, 9, or 21 dpi (SARS-CoV nucleocapsid protein
[brown staining]; original magniﬁcation, 400 ). (D) Temporal change of pulmonary virus titer in the following: aged BALB/c mice (green); untreated SCID mice (blue);
SCID mice transplanted with splenocytes from naïve BALB/c mice (yellow); or SCID mice transplanted with splenocytes from sensitized BALB/c mice (red). Splenocytes
(4107 cells) were administered intravenously to each recipient SCID mouse 1 day before infection. Data are presented as mean7S.D. (n¼4/time point). npo0.05
(compared with naïve splenocyte-transplanted SCID mice at 2 dpi or with other groups at 4 dpi). (E) Representative lung sections (hematoxylin and eosin staining;
section thickness 4 μm) from each group in (D) at 9 dpi. SPL, splenocyte. For all micrographs, original magniﬁcation is 200 . (F) Flow cytometry analysis of CD4 and
CD8 expression on lymphocytes isolated from spleen 1 day after administration of the indicated mAb. (G) Virus titers in the lung of untreated (white), CD8þ cell-
depleted (light gray), CD4þ cell-depleted (dark gray), or CD4þ and CD8þ cell-depleted BALB/c mice (black) at 6 and 9 dpi. The limit of detection was o1103 TCID50/g
lung. Data are presented as mean7S.D. (n¼3–7/time point).
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SARS-CoV in animal models. (Casazza et al., 2006; Landais et al., 2004;
Christensen et al., 1999; Nicholls et al., 2003; Lee et al., 2003; Peiris
et al., 2004). Furthermore, we examined whether B cells play an
important role in the elimination of SARS-CoV in the lung by using
SCID mice that were transplanted with B cells of naïve BALB/c mice
before infection with the virus. Although the CD19þ cell-transplanted
SCID mice (CD19þ cells; purity 98.3%) did not decrease the pulmonary
SARS-CoV titer by 9 dpi, the SCID mice that had received a combina-
tion of both cell fractions (the CD19þ cell subset and the residual cell
subsets (CD19 subsets containing T cells)) exhibited marked
decreases in pulmonary SARS-CoV titer (to less than 1104 TCID50/g
lung tissue; Fig. 3A). SCID mice that received the residual cell subsets
alone (i.e., a CD19 fraction) also did not exhibit decreased pulmonary
SARS-CoV titer by 9 dpi (Fig. 3A).
To examine whether post-infection treatment with anti-SARS-
CoV Abs could control SARS-CoV infection, SCID mice were infected i.
n. with SARS-CoV and then were administered intraperitoneally (i.p.)
twice with 0.5 mL of rabbit anti-spike (S) protein antiserum (neu-
tralization titer [NT50]4300 against SARS-CoV; raised against SARS-
CoV S protein expressed via recombinant vaccinia virus (Kitabatake
et al., 2007; Yasui et al., 2008)). The group treated with anti-S protein
antiserum eliminated SARS-CoV infection, but neither control group
(treated with normal rabbit serum or rabbit antiserum raised against
non-recombinant vaccinia virus) eliminated SARS-CoV infection
(Fig. 3B). The decrease of pulmonary-infected SARS-CoV titer in the
anti-S protein antiserum-treated SCID mice was conﬁrmed by
quantitative RT-PCR for the detection of mRNA of the nucleocapsid
(N) protein-encoding gene of SARS-CoV (Fig. 3C). These results
suggested that the production of anti-SARS-CoV Abs by B cells,
which is a T cell-dependent process, plays an important role in the
control of SARS-CoV infection.
Neutralizing activity of antisera against SARS-CoV is not essential for
the control of SARS-CoV infection
Multiple studies have demonstrated that neutralizing Abs are
important humoral factors for the control of viral infection. As
shown in Fig. 3B, administration of high-dose neutralizing Abs
(NT504300; 0.5 mL2 doses) eliminated SARS-CoV, although the
antisera used were derived from other animal species. However,
when BALB/c mice eradicated the SARS-CoV infection (9 dpi), the
neutralization titer of antiserum from these BALB/c mice achieved
an NT50 of 40–80 (Yasui et al., 2008). To investigate whether the
neutralizing activity of Abs is crucial for controlling SARS-CoV
infection, the SARS-CoV-infected SCID mice were administered i.p.
at 6 dpi with lower doses of either mouse anti-SARS-CoV antiserum
or rabbit anti-S protein antiserum. For this experiment, the neu-
tralization titers of both mouse anti-SARS-CoV antiserum and rabbit
Fig. 2. Antiviral effect of CD4þ cells is indirect. (A) Temporal change of virus titer in the lung of young BALB/c mice (closed circles) and young nude mice (open circles). Data
are presented as mean7S.D. (n¼5/time point). N.D.: not detected. (B) Representative lung sections (hematoxylin and eosin staining; section thickness 4 μm) from young
BALB/c mice at 9 dpi (a) and 20 dpi (b) and young nude mice at 9 dpi (c) and 20 dpi (d). For all micrographs, original magniﬁcation is 200 . (C) Virus titer in the lung of
CD4þ cell-transplanted SCID mice was determined at 6 and 9 dpi. Data are presented as mean7S.D. (n¼5/time point). CD4þ cells (1107 cells) were administered to each
recipient SCID mouse intravenously 1 day before challenge. (D) Virus titer in the lung of nude mice adoptively transplanted with CD4þ cells (gray) or residual cells (CD4
cells; black), determined at 6 and 9 dpi. Untreated nude mice (white) were included as a control. CD4þ cells (1107 cells) or residual cells (3107 cells) were administered
to each recipient nude mouse intravenously 1 day before challenge. Data are presented as mean7S.D. (n¼3/time point). (E) Pulmonary virus titer of IFN-γ deﬁcient mice
and splenocyte-transplanted SCID mice at 6 and 9 dpi. Splenocytes (4107 cells) derived from IFN-γ deﬁcient mice were administered to each recipient SCID mouse
intravenously 1 day before challenge. Data are presented as mean7S.D. (n¼3/time point). N.D.: not detected. SPL, splenocyte.
F. Yasui et al. / Virology 454-455 (2014) 157–168160
Fig. 3. Clearance of SARS-CoVwith anti-SARS-CoV antibodies does not correlate with neutralizing activity. (A) Virus titers in the lung of SCIDmice adoptively transplanted with CD19þ
cells (white), residual cells (CD19 cells; gray), or both CD19þ and CD19 cells (black) were determined at 6 and 9 dpi. CD19þ cells (2107 cells) and/or residual cells (2107 cells)
were administered to each recipient SCIDmouse intravenously 1 day before challenge. Data are presented as mean7S.D. (n¼3–4mice/time point). (B) Antiviral effect of post-infection
administration of rabbit anti-S (spike) protein of SARS-CoV antibody (NT504300) (at 6 and 8 dpi) assessed as pulmonary virus titer at 9 dpi; untreated (white), normal rabbit serum-
injected (gray), anti-vaccinia virus (VACV) antiserum (black), or anti-recombinant vaccinia virus expressing S protein of SARS-CoV (rVV-S) antiserum-injected (anti-S protein of SARS-
CoV antiserum-injected). Data are presented as mean7S.D. (n¼5 mice/time point). N.D.: not detected. (C) Quantitation of mRNA of nucleocapsid protein-encoding gene of SARS-CoV
in the lung of SCID mice administered with anti-S protein antiserum. Total RNA extracted from the lungs was used to measure mRNA of nucleocapsid protein-encoding gene of SARS-
CoV by quantitative RT-PCR. Each symbol indicates an individual subject. Heavy horizontal bars indicate the mean values for each treatment. npo0.05. (D) Antiviral effect of post-
infection treatment with murine anti-SARS-CoV antiserum or rabbit anti-S (spike) protein of SARS-CoV antiserum at low neutralization titer in SCID mice infected with SARS-CoV. A
single dose of antiserum (0.2 mL) was injected at 6 dpi at low (NT50¼13.3) or high (NT50¼40) neutralization titer. Two doses of antiserum (0.2 mL/dose) were injected at 6 and 8 dpi at
high (NT50¼40) neutralization titer. The limit of detection was o1103 TCID50/g lung. Data are presented as mean7S.D. (n¼4 mice/group). npo0.05. N.D.: not detected.
(E) Relationship between pulmonary virus titer and neutralization titer against SARS-CoV in sera of SCID mice adoptively transplanted with murine anti-SARS-CoV antiserum or rabbit
anti-S protein of SARS-CoV antiserum at 9 dpi; untreated group (open diamond), single dose of low-dose (NT50¼13.3, 0.2 mL; 6 dpi) murine anti-SARS-CoV antiserum (gray circle),
single dose of high-dose (NT50¼40, 0.2 mL) murine anti-SARS-CoV antiserum (gray triangle), two doses of high-dose (NT50¼40, 0.2 mL2; 6 and 8 dpi) murine anti-SARS-CoV
antiserum (gray square), single dose of high-dose rabbit anti-S protein antiserum (closed triangle), two doses of high-dose rabbit anti-S protein antiserum (closed square). Note that
symbol colors match classiﬁcations in panel (D).
anti-S protein antiserum were adjusted to NT50¼40; mouse anti-
SARS-CoV antiserum also was tested at NT50¼13.3. As shown in
Fig. 3D, the single injection (0.2 mL i.v., NT50¼40) of mouse SARS-
CoV antiserum, but not that of rabbit anti-S protein antiserum,
reduced the pulmonary SARS-CoV titer. The single injection of
mouse anti-SARS-CoV antiserum at an even lower neutralization
titer (0.2 mL, NT50¼13.3) also reduced the pulmonary virus titer by
greater than 100-fold compared with that of untreated animals.
Importantly, the SCID mice treated with rabbit anti-S protein
antiserum did not eliminate SARS-CoV by 9 dpi, although the
antisera of SCID mice treated with the rabbit antiserum clearly
demonstrated neutralization activity against SARS-CoV (Fig. 3E).
The inconsistency between the in vitro (neutralizing activity) and
in vivo (clearance of pulmonary SARS-CoV) activities of the rabbit
antiserum suggested that other effectors, besides anti-SARS-CoV
Abs, also might be required to control SARS-CoV infection.
Phagocytic cells are essential for the elimination of the SARS-CoV-
infected pulmonary cells in the presence of anti-SARS-CoV antibodies
To identify the effectors involved in the elimination of SARS-
CoV-infected pulmonary cells in our mouse models, we tested the
contribution of several candidate effectors. SARS-CoV-infected
BALB/c mice were depleted of the ﬁrst candidate, complement,
by the injection of cobra venom factor (CVF; 40 U/mouse) at 5 and
6 dpi. Despite the depletion of C3 from the serum of BALB/c mice
following CVF injection (Fig. 4A), CVF-treated BALB/c mice still
eliminated SARS-CoV by 9 dpi (Fig. 4B). These results demon-
strated that the complement–antibody complex is not required for
the control of SARS-CoV infection in this model.
We next investigated the contribution of NK cells to the
elimination of SARS-CoV by administering anti-IL-2Rβ mAb (TM-
β1), a treatment known to result in long-term depletion of NK
cells (Tanaka et al., 1993). We injected i.p. TM-β1 (100 mL of
ascites) into both SCID and BALB/c mice. Three days after TM-β1
treatment, NK cell-depleted BALB/c mice splenocytes were trans-
ferred adoptively into NK cell-depleted SCID mice. The SCID mice
were infected i.n. with SARS-CoV at 1 day after the splenocyte
transfer. As shown in Fig. 4C, NK cells were considerably depleted
in both the donor BALB/c mice (spleen) and the recipient SCID
mice. However, virus still was eradicated in this NK-depleted
model (Fig. 4D); thus, Ab-dependent cell-mediated cytotoxicity,
which requires NK cells, was excluded as a mechanism for the
elimination of SARS-CoV.
Other blood cells also may serve as effectors for the control of
SARS-CoV. Speciﬁcally, elevated levels of alveolar macrophages,
monocyte-derived inﬁltrating macrophages, and neutrophils were
observed in many SARS patients (Nicholls et al., 2003; Lee et al.,
2003). While these three cell types have been implicated in SARS
pathology, the role of these cell subsets in the control of SARS-CoV
infection is still unknown. To investigate the role of these myeloid
cells in the clearance of SARS-CoV-infected pulmonary tissue, each
subset of these myeloid cells was depleted by administration of a
speciﬁc mAb or reagent. Consistent with previous reports (Pribul
et al., 2008), alveolar macrophages were depleted for more than
5 days following i.n. administration of 100 μL of 30% clodronate
liposome (Fig. 5A). (Note that we used 30% clodronate liposome,
thereby avoiding the intensive inﬁltration of neutrophils seen with
administration of 100% clodronate liposome (Fig. 5A)). Neutrophils
(CD11bþ and Ly-6Ghi) and Gr-1int monocytes in blood and lung
were signiﬁcantly depleted for at least 3 days after i.p. treatment
with 250 μg of anti-Gr-1 mAb, whereas neutrophils alone
were depleted upon administration of anti-Ly-6G mAb (1A8)
(Fig. 5B and Daley et al., 2008). The Gr-1þ cell- and/or alveolar
macrophage-depleted groups failed to eliminate the pulmonary
SARS-CoV infection (Fig. 5C), whereas the alveolar macrophage-
depleted group showed partial elimination of the virus. In
contrast, the neutrophil-depleted BALB/c animals (anti-Ly-6G
mAb-treated mice) eliminated SARS-CoV by 9 dpi (Fig. 5C). Impor-
tantly, the neutralizing Ab titer of these cell-depleted mice was
comparable to that of untreated BALB/c mice (Fig. 5D, p¼0.37).
Similar results were obtained in murine anti-SARS-CoV antisera-
treated SCID mice that were administered with clodronate lipo-
some and/or anti-Gr-1 mAb (Fig. 5E). These results suggest that
phagocytic cells, especially monocyte-derived inﬁltrating macro-
phages, cooperate with anti-SARS-CoV Abs to provide control of
SARS-CoV infection in these mouse models.
Discussion
The outbreak of SARS in 2002–2003 resulted in over 8000
cases, with 10% mortality. The worst symptoms might correlate
with age-dependent defects of immune response, given that
mortality exceeded 50% in patients over 65 years of age (Peiris
et al., 2004). A recent study using MA15-infected mouse models
suggested that age-dependent increases of prostaglandin D2
expression in the lung may be associated with impaired immune
response (Zhao et al., 2011). Retrospective analyses of recovered
SARS patients suggests that patients who recovered from SARS
possessed speciﬁc acquired immunity based on both T and B cells
(Yang et al., 2006, 2007; Li et al., 2008; Fan et al., 2009). Notably,
most patients who recover from SARS had elevated and sustained
levels of neutralizing Abs, and patients with longer illnesses
exhibited lower levels of neutralizing Abs than did patients with
shorter durations of illness (Temperton et al., 2005; Ho et al.,
2005). Previous studies revealed that passive transfer of immune
serum to naïve animals prevented SARS-CoV replication in the
lower respiratory tract (Yang et al., 2004; Subbarao et al., 2004;
Kam et al., 2007; Zhu et al., 2007; Rockx et al., 2008, 2011). Taken
together, these results suggest that Ab responses likely play an
important role in determining the ultimate disease outcome of
SARS-CoV infection. Virus could be eradicated by direct binding of
the virus by the neutralizing Abs and/or by cooperation between
virus-speciﬁc Abs and other effector cells, including complement,
NK cells, and phagocytic cells. However, the actual mechanism
that controls the acute phase of SARS-CoV infection remained
unclear.
In this study, we found that rabbit antiserum raised against the
S protein of SARS-CoV exhibited signiﬁcantly lower efﬁcacy in the
control of the virus infection than mouse anti-SARS-CoV anti-
serum when similar neutralization titers against SARS-CoV were
transferred into recipient mice. Therefore, it appears that the
neutralization activity of Ab against SARS-CoV does not correlate
with the clearance efﬁcacy of the virus from infected murine lung.
On the other hand, some other antibody property (such as avidity)
may differ between the murine and rabbit antisera, given that the
former is a polyclonal species derived from SARS-CoV-infected
mice, while the latter was generated in rabbit against the
S protein. Further study will be needed to resolve this distinction.
In a Chinese hamster model of SARS, post-infection treatment (at
1 dpi) with 100 mg/kg of equine neutralizing F(ab')2 resulted in
only partial reduction of pulmonary viral titer, although prophy-
lactic treatment at a 10-fold lower dose was sufﬁcient to com-
pletely block SARS-CoV infection (Luo et al., 2007). This result
suggests that the anti-infective activity of a neutralizing Ab is
mediated primarily via prevention of SARS-CoV invasion; the
neutralizing Ab plays a lesser role in eliminating the virus after
establishment of infection.
Therefore, we focused on the cooperation between anti-SARS-
CoV Abs and other effectors in the control of SARS-CoV infection.
Candidate effectors include complement (e.g., C3 and other
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members of the complement–antibody complex pathway), NK
cells (mediators of the Ab-dependent cell-mediated cytotoxicity
pathway), and Fc gamma receptor (FcγR)-bearing cells (notably
alveolar macrophages, monocytes [monocytes-derived inﬁltrating
macrophages], and neutrophils). A previous study reported that
anti-Gr-1 mAb (RB6-8C5) recognizes not only neutrophils but
also additional leukocyte populations, including monocytes
(Daley et al., 2008). Therefore, we used both anti-Gr-1 mAb and
neutrophil-speciﬁc mAb (anti-Ly-6G mAb) to discriminate mono-
cytes and neutrophils. We tested the role of these candidates by
selective depletion of a mouse infection model for various factors
using CVF (complement depletion), anti-IL-2Rβ mAb (TM-β1;
NK cell depletion), clodronate liposomes (alveolar macrophage
depletion), anti-Gr-1 mAb (monocytes/neutrophil depletion), or
anti-Ly6G mAb (neutrophil depletion) before or after SARS-CoV
infection. Notably, the groups administered with clodronate lipo-
some or anti-Gr-1 mAb, but not those treated with anti-Ly-6G
mAb, failed to eliminate SARS-CoV from their lungs by 9 dpi. Our
results indicated that phagocytic cells such as monocyte-derived
inﬁltrating macrophages and partially alveolar macrophages, but
not neutrophils, play a crucial role in the elimination of SARS-CoV-
infected pulmonary cells in mice. Although little is known about
Fig. 4. Complement and NK cells are not required for the control of pulmonary-infected SARS-CoV. For panels (A) and (B), complement was depleted in BALB/c mice by
administering cobra venom factor (CVF) intravenously at 5 dpi and 6 dpi; control animals were administered phosphate-buffered saline (PBS) by the same regimen.
(A) Concentration of complement 3 in the sera of BALB/c mice was measured by ELISA. Data are presented as mean7S.D. (n¼4/time point). (B) Pulmonary virus titer of aged
BALB/c mice treated with CVF (complement depletion), determined at 6 and 9 dpi. Data are presented as mean7S.D. (n¼4/group). N.D.: not detected. For panels (C) and
(D), NK cells were depleted by administering anti-IL-2Rβ Ab (TM-β1). Untreated BALB/c mice were used as controls. (C) Flow cytometric analysis of CD49b and TCRβ
expression of leukocytes in the spleen of BALB/c mice 3 days after the administration of TM-β1 and in spleen and lung of SCID mice 4 days after the administration of TM-β1.
Representative diagrams are shown. (D) Splenocytes from BALB/c mice administered with TM-β1 were adoptively transplanted into SCID mice that were previously
administered with TM-β1 to deplete NK cells. Pulmonary virus titers of BALB/c splenocyte-transplanted SCID mice were determined at 6 and 9 dpi. Data are presented as
mean7S.D. (n¼3–4/group). N.D.: not detected.
F. Yasui et al. / Virology 454-455 (2014) 157–168 163
Fig. 5. Cooperation of phagocytic cells and antibodies is essential for the eradication of SARS-CoV infection. (A) Depletion of alveolar macrophages by intranasal
administration of clodronate liposome. BALB/c mice were administered intranasally with 0.1 mL of 30% (left graph) or 100% clodronate liposome (right graph). Where
applicable, dilution of clodronate liposome (to 30%) was performed using Dulbecco's PBS. Numbers of cells in bronchoalveolar lavage ﬂuid (BALF) were determined by
counting cell numbers (white, alveolar macrophages; black, other cells including neutrophils) following cytospin preparation. Data are presented as mean (n¼2/time point).
(B) Depletion of neutrophils and monocytes with anti-Gr-1 monoclonal antibody (mAb) or anti-Ly-6G mAb (respectively). The panel shows results of ﬂow cytometric analysis
of CD11b and Gr-1 expression of leukocytes in blood and lung of BALB/c mice at 3 days after the administration of anti-Gr-1 mAb or anti-Ly-6G mAb. Untreated BALB/c was
used as a control. Representative diagrams are shown. (C) Pulmonary virus titers of BALB/c mice that were administered anti-Ly-6G mAb (depletion of neutrophils),
clodronate liposome (depletion of alveolar macrophages; gray), anti-Gr-1 mAb (depletion of Gr-1þ cells; dark gray), or both clodronate liposome and anti-Gr-1 mAb (black)
were determined 9 dpi. Data are presented as mean7S.D. (n¼3–7/group). N.D.: not detected. CL: clodronate liposome. (D) Neutralization titers against SARS-CoV in antisera
of SARS-CoV-infected mice at 9 dpi. (E) Pulmonary virus titers of passively immunized SCID mice (i.e., injected with anti-SARS-CoV antiserum) that were administered
clodronate liposome (CL; depletion of alveolar macrophages; gray), anti-Gr-1 mAb (depletion of Gr-1þ cells; dark gray), or both CL and anti-Gr-1 mAb (black) were
determined at 9 dpi. Data are presented as mean7S.D. (n¼3–6/group). N.D.: not detected.
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host defense mechanisms in the acute phase of SARS clinical
infection, inﬁltration of large numbers of macrophages into the
lungs of SARS patients was observed (Nicholls et al., 2003; Franks
et al., 2003). Those reports are consistent with our results,
although further studies are necessary to clarify the mechanism
(s) of elimination of SARS-CoV via cooperation of phagocytic cells
and SARS-CoV-speciﬁc antibodies.
While a previous study (Chen et al., 2010) and our results
(Fig. 1G) showed that depletion of CD8þ T cell at the time of
infection had little effect on viral replication or clearance, Zhao
and Perlman (2010) reported that adaptive transfer of CD8þ T cells
sensitized with the SARS-CoV MA 15 strain into naïve BALB/c mice
completely protected the recipients from a subsequent challenge
with lethal dose of MA15. Zhao et al. also showed that the
diminished virus-speciﬁc CD8þ T cell responses resulted from
inefﬁcient activation of alveolar macrophages and respiratory
dendritic cells in lethal diseases (Zhao et al., 2009, 2012; Zhao
and Perlman, 2010). Their studies also demonstrated suboptimal
responses of CD4þ T cell responses as well as CD8þ T cells,
implying a critical role for antibody responsiveness in the MA15
infection model. In addition, while depletion of alveolar macro-
phages before MA15 infection completely protected mice from this
lethal challenge, the depletion of alveolar macrophages at 2 days
after MA15 infection appeared to exacerbate mortality (Zhao et al.,
2009). Therefore, our ﬁndings would be rendered more persuasive
by the inclusion of additional animal infection experiments using
other patient isolates, such as the Urbani strain, and mouse-
adapted strains, such as MA15, of SARS-CoV.
Although the importance of other effector cells for clearance of
coronaviruses is still unknown, there are several reports that
showed the implication of FcγR-bearing cells in the clearance of
inﬂuenza virus. Fujisawa (2008) noted that neutrophils play a
crucial role in the control of inﬂuenza virus infection by coopera-
tion with anti-inﬂuenza virus antibodies. It also has been reported
that FcRγ / mice were highly susceptible to inﬂuenza virus
infection, even in the presence of anti-inﬂuenza Abs from immune
FcRγþ /þ mice (Huber et al., 2001). These results indicate the
important role of FcγR-bearing effector cells in the clearance of
inﬂuenza virus infections. In addition, we here demonstrated that
both monocyte-derived macrophages (inﬁltrating-type) and par-
tially alveolar macrophages (resident-type) contribute to the
elimination of SARS-CoV-infected pulmonary cells in the presence
of anti-SARS-CoV Abs.
Alveolar macrophages play a central role in maintaining lung
homeostasis and are considered the ﬁrst line of host defense
against respiratory microbes. Marked enhancement of the virus
titer was reported in other respiratory virus infection models
(Pribul et al., 2008; Tumpey et al., 2005). On the other hand,
monocytes circulate throughout the body in anticipation of
inﬂammation and infection. Murine monocytes are reported to
comprise two distinct subpopulations with different phenotypes:
CX3CR1loCCR2þGr-1þ and CX3CR1hiCCR2-Gr-1 monocytes
(Geissmann et al., 2003). On inﬁltration of the infection site,
Gr-1þ inﬂammatory monocytes can give rise to various dendritic
cells and macrophage types (Varol et al., 2009). Iijima et al. (2011)
demonstrated that Gr-1þ monocyte-derived APCs are required to
elicit IFN-γ secretion from effector Th1 cells, thus mediating host
protection against HSV-2 infection. Lin et al. (2008) reported that
monocyte-derived DCs and macrophages cause immune pathology
rather than viral clearance during inﬂuenza virus infection. In
contrast, Gr-1þ monocyte-derived cells are involved in the clear-
ance of SARS-CoV infection, although the role of Gr-1þ monocyte-
derived cells in the development of pathogenesis during SARS-CoV
infection remains unknown.
In conclusion, we demonstrate a crucial role for cooperation of
antigen-speciﬁc antibodies and phagocytic cells (monocyte-derived
inﬁltrating macrophages and partially alveolar macrophages) in the
elimination of SARS-CoV in mouse models of infection. Our ﬁndings
provide a better understanding of the mechanism(s) by which host
defenses control SARS-CoV infection. Ideally, this information can
contribute to the development of novel therapeutic protocols or
treatments for SARS.
Materials and methods
Virus and cells
These studies used the SARS-CoV Vietnam/NB-04/2003 strain.
This strain, originally isolated from a single patient's throat lavage,
was kindly provided by Dr. Mai Quynh Le (Hong et al., 2004) and
further subcultured in Vero E6 cells grown in MEM (Nissui
Pharmaceutical Co. Ltd., Tokyo, Japan) containing 5% FCS. All work
using SARS-CoV was performed in Biosafety Level 3 facilities by
personnel wearing powered air-purifying respirators (Shigematsu
Co., Ltd., Tokyo, Japan).
Mouse infection model
SCID mice (female, 7–8 weeks old) were purchased from CLEA
Japan, Inc. (Tokyo, Japan). BALB/c mice (female, 46 months old
and 6–7 weeks old) and nude mice (female, 6 weeks old) were
purchased from SLC (Shizuoka, Japan). The IFN-γ deﬁcient mouse
(BALB/c background) was the kind gift of Prof. Iwakura (The
Institute of Medical Science, The University of Tokyo and Tokyo
University of Science). On study day 0, mice were inoculated i.n.
with SARS-CoV at 1105 TCID50 (20 μL) per mouse. At serial time
points, mice were sacriﬁced under anesthesia following terminal
blood collection, and the lungs were recovered. Portions of the
tissues were frozen immediately at 80 1C or ﬁxed in 10% buffered
formalin. Blood was used for the in vitro neutralization assays and
adoptive transfer experiments. All animal experiments using mice
were approved by the Animal Experiment Committee at The
Institute of Medical Science, The University of Tokyo, and were
performed in accordance with the animal experimentation guide-
lines of The Institute of Medical Science, The University of Tokyo.
Depletion of immunocompetent cells
To conﬁrm the depletion efﬁcacy of anti-CD4 mAb (GK1.5;
100 mL of ascites) or anti-CD8 mAb (53.6; 100 mL of ascites), BALB/c
mice were injected i.v. with the indicated dose volumes. At 1 day
after administration of the respective mAb, spleen-derived lym-
phocytes were analyzed by ﬂow cytometry for expression of CD4
and CD8. To test efﬁcacy against SARS-CoV infection, the anti-CD4
mAb and/or anti-CD8 mAb was injected i.v. on days 3, 0, þ3 and
þ6 with respect to the SARS-CoV challenge. For experiments
examining the depletion of Gr-1þ (Ly-6Gþ and Ly-6Cþ) cells,
anti-Gr-1 mAb (250 mg, RB6-8C5; rat IgG2b) was injected i.p. 6
days after SARS-CoV challenge (Fujisawa, 2008). The hybridoma
RB6-8C5 was obtained from the Cell Resource Center for Biome-
dical Research, Institute of Development, Aging, and Cancer,
Tohoku University (Miyagi, Japan). Anti-IL2Rβ mAb (TM-β1), used
for the depletion of NK cells (Tanaka et al., 1993), was the kind gift
of Prof. Miyasaka (Osaka University, Japan). TM-β1 (100 mL of
ascites) was injected i.p. 3 days before adoptive transfer of BALB/
c mice splenocytes into both SCID and BALB/c mice. Anti-Ly6G
mAb (1 mg, 1A8; rat IgG2a [purchased from Bio-XCell Co., Ltd.])
was injected i.p. 6 days after SARS-CoV challenge to deplete Ly-
6Gþ cells (neutrophils) (Daley et al., 2008). The depletion of the
respective immunocompetent cells was conﬁrmed by ﬂow cytometric
analysis. One hundred microliters of 30% clodronate liposome
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suspension was injected i.n. in mice 6 days after SARS-CoV challenge
to deplete alveolar macrophages (Pribul et al., 2008). The numbers of
AMs were quantiﬁed in the bronchoalveolar lavage ﬂuid (BALF). To
deplete complement, cobra venom factor (CVF; 40 U/mouse, a gift of
Prof.Okada, Nagoya City University, Japan) was injected i.p. in SCID
mice both 5 and 6 days after SARS-CoV challenge (Pleyer et al., 1992).
Adoptive transfer of immunocompetent cells
Splenocytes were isolated from SARS-CoV-infected (9 dpi;
sensitized) or naïve BALB/c mice (over 6 months old); the resulting
cells then were administered (at 4107 cells/animal) to recipient
naïve SCID mouse i.v. 1 day before challenge. Splenocytes from NK
cell-depleted BALB/c mice also were administered to recipient
NK cell-depleted SCID mice as described above. CD4þ cells
(1107 cells) were isolated from the spleen of naïve BALB/c mice
using anti-CD4 magnetic beads, followed by puriﬁcation with an
AutoMACS sorter (Miltenyi Biotech, Bergisch Gladbach, Germany).
Isolated CD4þ cells (496% purity) were adoptively transplanted
into each recipient naïve SCID or nude mouse. In addition,
splenocytes of naïve BALB/c mice were divided into the CD19þ
cells (B cells) and residual cells (CD19 cells, including T cells)
using anti-CD19 magnetic beads (Miltenyi Biotech). The B cells
(CD19þcells; 2107 cells/mouse) and/or the residual cells (CD19
cells; 2107 cells/mouse) then were adoptively transplanted into
the recipient naïve SCID mice.
Passive transfer of antisera
In our previous study, New Zealand White rabbits were immu-
nized with a recombinant vaccinia virus LC16m8 strain expressing
the gene for the S protein of SARS-CoV (Kitabatake et al., 2007). The
resulting antisera (rabbit anti-S protein) showed high neutralizing
activity against SARS-CoV (NT504300). As negative controls for this
rabbit anti-S antiserum, we used normal rabbit serum and/or rabbit
antiserum against vaccinia virus strain LC16m8. Mouse anti-SARS-
CoV antiserumwas obtained from BALB/c mice at 9 days after SARS-
CoV infection, at which point the antiserum exhibited NT50¼40.
For passive transfer, each recipient naïve mouse received 0.2–
0.5 mL of rabbit anti-S protein antiserum or mouse anti-SARS-CoV
antiserum, administered i.v. at 6 dpi (or at 6 and 8 dpi).
Determination of viral titers in the lung
The SARS-CoV titers in the murine lung were determined as
described previously (Yasui et al., 2008). Brieﬂy, lung tissue
samples were homogenized in 10 volumes of Leibovitz 15 medium
(Invitrogen, CA, USA). The homogenate was centrifuged at 400 × g
for 10 min at 4 1C. The supernatant was collected and stored at
80 1C until use. Serial 10-fold dilutions of the supernatant were
added to Vero E6 cells seeded on 96-well plates. After 6 days of
incubation, the cells were ﬁxed with 10% buffered formalin. Viral
titers were determined as the 50% endpoint dilution of the
homogenate that induced the cytopathic effect, and were
expressed as TCID50 per gram of tissue. The method used for
endpoint calculation was that described by Reed and Muench
(1938).
In vitro neutralization assay for SARS-CoV
Serial 2-fold dilutions of heat-inactivated sera (41:4) were
mixed with equal volumes of 200 TCID50 of SARS-CoV and
incubated at 37 1C for 1 h. Vero E6 cells then were infected with
100 mL of the virus-serum mixtures in 96-well plates. After 6 days
of incubation, the neutralization titer was determined as the
endpoint dilution of the serum at which there was 50% inhibition
of the SARS-CoV-induced cytopathic effect. The method used for
endpoint calculation was that described by Reed and Muench
(1938).
Lung histopathology and immunohistochemistry
In accordance with a previous report, 10% formalin-ﬁxed lung
tissues of the SARS-CoV-infected mice were embedded in parafﬁn
(Yasui et al., 2008). Parafﬁn block sections (4-μm thickness) were
stained with hematoxylin and eosin. Antigen retrieval was per-
formed by autoclaving sections in 10 mM citrate buffer (pH 6.0) for
20 min, and then the sections were immersed in 3% hydrogen
peroxide (H2O2) at room temperature (RT) for 5 min to inactivate
endogenous peroxidase. The sections were blocked with 5% skim
milk in Tris-buffered saline containing 0.1% Tween-20 at RT for
30 min, and then were incubated (overnight at 4 1C) with 1 mg/mL
of anti-N protein of SARS-CoV polyclonal antibody (pAb) (IMG548;
IMGENEX, San Diego, CA, USA). Secondary labeling was performed
by incubation (at RT for 2 h) with 1:1000 donkey anti-rabbit IgG
(GE Healthcare, Buckinghamshire, UK), followed by color develop-
ment with 3,3'-diaminobenzidine in 50 mM Tris–HCl (pH 7.6) for
30 min. Nuclear staining was performed with hematoxylin solution.
Slides were imaged using an Axio Imager A2 microscope (Carl Zeiss
Inc., Oberkochen, Germany).
Extraction of total RNA and quantitative RT-PCR
Total RNA samples were extracted from lung using the illustra
RNAspin Midi isolation kit (GE Healthcare) according to the
manufacturer's instructions. Messenger RNA levels for the N
protein-encoding gene of SARS-CoV were measured using the
TaqMan EZ RT-PCT kit (Applied Biosystems, Branchburg, NJ,
USA). Each 25 mL reaction mixture contained 5.0 mL 5 TaqMan
EZ buffer, 3.0 mL 25 mM Mn(OAc)2, 0.25 mL 1 U/mL AmpErase UNG
(uracil N-glycosylase), 1.0 mL 2.5 U/mL of rTth DNA polymerase,
3.0 mL dNTP mix (10 mM dATP, 10 mM dCTP, 10 mM dGTP, and
20 mM dUTP), 0.25 mL 10 mM probe, 0.25 mL each 50 mM forward
and reverse primers, 7.0 mL nuclease-free water, and 5.0 mL nucleic
acid extract. Ampliﬁcation was carried out in 96-well plates on the
ABI Prism 7700 and Sequence Detection System software ver. 1.7.
Thermocycling conditions consisted of 2 min at 50 1C for UNG
treatment, 30 min at 60 1C for reverse transcription, 5 min at 95 1C
for deactivation of UNG, and 50 cycles of 15 s at 95 1C and 1 min at
60 1C for ampliﬁcation. Each run included pEFMyc-His-SARS-N
plasmid (at 101, 102, 103, 104, 106, and 108 copies/5 mL) to provide a
standard curve and at least one no-template control. The primers
and probe used in this study were as follows: forward primer,
5'-GGAGCCTTGAATACACCCAAAG-3'; reverse primer, 5'-GCACGG-
TGGCAGCATTG-3'; probe, 5'-(FAM)-CCACATTGGCACCCGCAATCC-
(TAMRA)-3'.
Quantitation of complement C3 serum level
The depletion of complement was quantiﬁed by enzyme-linked
immunosorbent assay (ELISA) for mouse complement C3 (Kamiya
Biomedical Company, Seattle, WA, USA).
Statistical analysis
Data are presented as mean7standard deviation (SD), where
applicable. Inferential statistical analysis was performed by One-
Way ANOVA, followed by Tukey's test. Non-parametric analysis
was performed using the Kruskal–Wallis test, followed by Mann–
Whitney's U test. A p valueo0.05 was considered statistically
signiﬁcant. All statistical calculations were performed with SPSS
Statistics 17.0 software (SPSS Inc., Chicago, IL, USA).
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